Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-020686

CHIEF FINANCIAL OFFICER sold 991 shares at $27.53 ($27,281)

  • CHIEF FINANCIAL OFFICER acquired 991 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hohl Benjamin · CHIEF FINANCIAL OFFICER

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2024-07-31 Exercise or conversion : show line 1 in the form 10b5-1 +991 $2.48 $2,458 991 D
2024-07-31 Sale : show line 2 in the form 10b5-1 −991 $27.53 $27,281 0 D
Open-market sales · 991 sh · avg $27.53 · $27,281

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-07-31 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −991 203,379 D
Loading xslF345X05/form4-08022024_110825.xml…